FDA Warns Novo Nordisk Over Potential Unreported Ozempic Side Effects, Deaths

Novo Nordisk received a warning letter from the U.S. FDA for failing to report adverse events potentially linked to Ozempic, including two deaths and one suicide, per a company press release. The enforcement action raises regulatory and litigation risk for the company and could pressure the stock and the commercial momentum of its weight-loss franchise; monitor for fines, follow-up FDA actions, and any impact on labeling or sales guidance.

Analysis

Novo Nordisk received a warning letter from the U.S. FDA for failing to report adverse events potentially linked to Ozempic, including two deaths and one suicide, per a company press release. The enforcement action raises regulatory and litigation risk for the company and could pressure the stock and the commercial momentum of its weight-loss franchise; monitor for fines, follow-up FDA actions, and any impact on labeling or sales guidance.